Researcher
Marc Peeters
- Research Expertise (University of Antwerp):My expertise is in the field of oncology or cancer research. It is mainly focused on clinical translational research. This domain is very broad and ranges from bio-research to clinical studies
- Keywords (University of Antwerp):ONCOLOGY, Medicine
- Disciplines (Ghent University):Endocrinology and metabolic diseases, Paediatrics and neonatology, Nursing
- Disciplines (University of Antwerp):Cancer therapy, Cancer biology, Cancer diagnosis, Cancer epidemiology, Cancer prevention
- Research techniques (University of Antwerp):Making protocols for studies. (Statistical) analysis of results
- Users of research expertise (University of Antwerp):Other researchers in the field. Students Pharma and Biotech companies
- See also: Marc Peeters (Ghent University)
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Responsible
From1 Oct 2009 → 31 Dec 2018 - Department of Internal medicine (Department)
Member
From1 Oct 2000 → 30 Sep 2018
Projects
51 - 60 of 67
- Investigation of DFNA5 as potential biomarker and tumour suppressor gene in 4 solid tumour types.From1 Oct 2014 → 30 Sep 2016Funding: FWO fellowships
- Molecular analysis of cell free circulating DNA (cfDNA) and/or circulating tumour cells (CTC) as 'liquid biopsy' for predictive biomarker assessment in patients with metastatic colorectal cancer (mCRC).From1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- Prognostic and predictive biomarker analysis in mCRC KRAS wild type patients treated in first line with Erbitux (Cetixumab) in combination with standard chemotherapy in daily clinical practice in Belgium.From1 Sep 2013 → 31 Aug 2017Funding: Nonprofit institution or equivalents
- Addition of WT1 mRNA-loaded autologous dendritic cell immunotherapy to adjuvant temozolomide chemotherapy after maximal, safe surgical resection and chemoradiation for newly diagnosed glioblastoma patients.From1 Sep 2013 → 31 Aug 2018Funding: Nonprofit institution or equivalents
- Overcoming resistance to mTOR inhibition in pancreatic neuroendocrine tumors: an analysis of the PI3K-Akt-mTORpathway beyond rapalogs.From1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Polo-like kinase 1 as a target for cancer treatments: focus on combination therapies and the role of the hypoxic tumour micro environment.From1 Jan 2013 → 31 Dec 2013Funding: BOF - Other initiatives
- Functional secretome analysis in pancreatic carcinoma using proteomics and dynamic viability and motility assays.From1 Jan 2013 → 31 Dec 2013Funding: BOF - Other initiatives
- Targeting polo-like kinase 1 for cancer treatment: focus on combination therapy and the role of the hypoxic microenvironment.From1 Oct 2012 → 30 Sep 2016Funding: FWO fellowships
- Detection and molecular characterization of circulating tumour cells in patients with breast cancer.From1 Oct 2012 → 30 Sep 2014Funding: FWO fellowships
- VECTor/CT: simultaneous PET/SPECT/CT scanner for small animals.From28 Jun 2012 → 31 Dec 2017Funding: Own budget, for example: patrimony, inscription fees, gifts, Hercules - Small and Medium size research infrastructure, FWO Medium Size Research Infrastructure
Publications
1 - 10 of 385
- Bleeding and perforation complications after follow-up colonoscopies in faecal immunochemical test-based colorectal cancer screening(2024)
Authors: Thuy Ngan Tran, Joanna Bouchat, Marc Peeters, Bea Berghmans, Eric Van Cutsem, Guido Van Hal, Koen Van Herck, Sarah Hoeck
Pages: 26 - 48 - Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from t(2024)
Authors: C.S. Karapetis, H. Liu, M.J. Sorich, L.D. Pederson, E. Van Cutsem, T. Maughan, J.Y. Douillard, C.J. O'Callaghan, D. Jonker, C. Bokemeyer, et al.
- Hyperthermia in combination with emerging targeted and immunotherapies as a new approach in cancer treatment(2024)
Authors: Tine Logghe, Eke van Zwol, Benoit Immordino, Kris van den Cruys, Marc Peeters, Elisa Giovannetti, John-Paul Bogers
Pages: 1 - 35 - Auranofin repurposing for lung and pancreatic cancer(2024)
Authors: Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, et al.
Pages: 1 - 15 - Relationship between health-related determinants and adherence to breast and colorectal cancer screening(2024)
Authors: Allegra Ferrari, Thuy Ngan Tran, Sarah Hoeck, Marc Peeters, Mathijs Goossens, Guido Van Hal
Pages: 347 - 353 - Treatment of ambulatory patients with metastatic epidural spinal cord compression(2024)
Authors: Ruben Van den Brande, Dieter Thijs, Mark Bilsky, Marc Peeters
Pages: 175 - 184 - New developments in treating RAS-mutated metastatic colorectal cancer(2023)
Authors: Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Pages: 965 - 987 - Increasing adherence to prophylactic swallowing exercises during head and neck radiotherapy(2023)
Authors: Margot Baudelet, Frederic Duprez, Leen Van den Steen, Sandra Nuyts, Ann Goeleven, Caroline Vandenbruaene, Hanne Massonet, Alice Vergauwen, Heleen Bollen, Sarah Deschuymer, et al.
Pages: 886 - 895 - A Belgian population-based study reveals subgroups of right-sided colorectal cancer with a better prognosis compared to left-sided cancer(2023)
Authors: Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Pages: e331 - e340 - Implementation of PROs in daily oncology care before and during the SARS-CoV-2 pandemic(2023)
Authors: Marika Rasschaert, Marc Peeters, Peter Van Dam, Annelies J R Janssens
Number of pages: 120
Patents
1 - 6 of 6
- Combination immunotherapy of il-15 and cd40 agonist in cancer treatment (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation detection assay (Inventor)
- Methylation status of gasdermin E gene as cancer biomarker (Inventor)
- Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment (Inventor)
- Methylation status of gasdermin e gene as cancer biomarker (Inventor)